

PCTWORLD INTELLECTUAL PROPE
International Bt

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9607430A1

(51) International Patent Classification ⁶ :A61K 39/40 // (A61K 39/40, 31:415,
38:08, 38:12)

A1

(11) International Publication Number:

WO 96/07430

(43) International Publication Date:

14 March 1996 (14.03.96)

(21) International Application Number: PCT/US95/10335

(22) International Filing Date: 14 August 1995 (14.08.95)

(30) Priority Data:

08/300,918

6 September 1994 (06.09.94) US

(71) Applicant: GALAGEN, INC. [US/US]; 4001 Lexington Av-
enue North, Arden Hills, MN 55126 (US).(72) Inventors: BOSTWICK, Eileen, F.; 15430 Brockton Lane,
Dayton, MN 55327 (US). HOERR, Robert, A.; 885 Hunt
Farm Road, Long Lake, MN 55356 (US).(74) Agent: DAIGNAULT, Ronald, A.; Merchant, Gould, Smith,
Edell, Welter & Schmidt, P.A., 1000 Norwest Center, 55 E.
Fifth Street, St. Paul, MN 55101 (US).(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH,
CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE,
KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE,
CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ,
UG).

Published

With international search report.

(54) Title: THERAPEUTIC TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES

(57) Abstract

The effective treatment of *Clostridium difficile* associated diseases, such as *Clostridium difficile colitis*, pseudomembranous colitis and antibiotic associated diarrhea, by administering an antibody having specific activity against *Clostridium difficile colitis* and toxins thereof alone or in combination with vancomycin, bacitracin or metronidazole is herein described as well as pharmaceutical compositions therefor.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**THERAPEUTIC TREATMENT OF CLOSTRIDIUM DIFFICILE
ASSOCIATED DISEASES**

FIELD OF INVENTION

5 This invention relates to the treatment of
 Clostridium difficile associated diseases such as
 Clostridium difficile colitis, pseudomembranous colitis
 and antibiotic associated diarrhea by administration of
 specific antibodies in the form of oral and/or
10 pharmaceutical compositions.

BACKGROUND OF THE INVENTION

Clostridium difficile was first described in 1935
 as a gram-positive anaerobic bacillus. The bacterium
 was named "the difficult *clostridium*" because it
15 resisted early attempts at isolation and grew very
 slowly in culture.

 The bacterium became unnoticed until approximately
 the 1960's and 1970's where there occurred a rise in
 antibiotic associated pseudomembranous colitis due to
20 wide usage of broad-spectrum antibiotic agents such as
 lincomycin and clindamycin. These antibiotics were
 found to cause diarrhea in approximately 10% of the
 patients and pseudomembranous colitis in approximately
 1%. It is now clear that *C. difficile* is responsible
25 for colitis in humans, antibiotic associated diarrhea
 and virtually all cases of pseudomembranous colitis.

 The disease develops as a result of the production
 of two large toxins, toxin A (M_r , 308,000) and toxin B
 (M_r , 279,000), by the organism in the colon (Barroso, et
30 al., Nucleic Acids Res., 18:4004; Dove, et al., Infect.
 Immun., 58:480-488; Lyster, et al., Clin. Microbiol.
 Rev., 1:1-18). Toxin A is believed to cause most of the
 gastrointestinal symptoms because of its enterotoxic
 activity in experimental animals (Borriello, et al.,
35 Microecol. Ther., 15:213-236; Lyster, et al., Infect.
 Immun., 35:1147-1150; Lyster, et al., Infect. Immun.,
 47:349-352). There is some evidence suggesting that the
 toxins act synergistically during the course of the
 disease and that the initial tissue damage caused by

toxin A allows toxin B to exert its toxic effect (Lyerly, et al., Infect. Immun., 47:349-352).

Most patients with *C. difficile* disease are treated effectively with vancomycin, bacitracin, or
5 metronidazole. Relapses occur in about 10-20% of the cases, however, indicating that antibiotic therapy is not always completely effective. As a result, research on alternative types of therapy is continuing.

Saccharomyces boulardii, a yeast used to treat
10 gastrointestinal illness, has shown promising results as a probiotic for the treatment of the disease in humans and in experimental animals (Corthier, et al., Can. J. Microbiol., 32:894-896; Elmer, et al., Antimicrob. Agents Chemother., 31:129-131; Kimmey, et al., Dig. Dis. Sci., 35:897-901; Surawicz, et al., Gastroenterology, 96:981-988; Toothaker, et al., Antimicrob. Agents Chemother., 26:552-556). The actual manner in which the yeast confers protection is unclear, although it has
15 been reported that the yeast must be viable in order to provide protection (Lucas, et al., Presented at the 15th International Congress on Microbial Ecology of Disease, 7 to 9 September 1990, Ioannina, Greece).

Immunoprophylaxis has also been suggested as a type of treatment. It is known that vaccination against toxins
25 A and B stimulates active immunity against *C. difficile* disease in experimental animals (Ferne, et al., Dev. Biol. Stand., 53:325-332; Libby, et al., Infect. Immun., 36:822-829). At the present time, however, suitable vaccines against the organism and its toxins have not
30 been developed for individuals at high risk, and it is still unclear whether active immunization is appropriate. Alternatively, treatment by passive immunization has been suggested. In preliminary studies, serum antibodies against a toxigenic isolate of
35 *C. difficile* protected hamsters against *C. difficile* disease when administered orally to the animals. Thus,

passive immunity may be beneficial for prophylactic treatment.

Passive immunization with bovine antibodies has been examined as a possible alternative therapy in the treatment of other infectious diseases of the gastrointestinal tract, including diseases caused by rotavirus, enteropathogenic and enterotoxigenic *Escherichia coli*, *Vibrio cholerae*, and *Cryptosporidium parvum*, and the results indicate that antibodies administered in this manner provide protection (Boesman-Finkelstein, et al., Infect. Immun., 57:1227-1234; Brussow, et al., J. Clin. Microbiol., 25:982-986; Fayer, et al., Infect. Immun., 58:2962-2965; Hilpert, et al., J. Infect. Dis., 156:158-166; Mietens, et al., Eur. J. Pediatr., 132:239-252; Tacket, et al., N. Engl. J. Med., 318:1240-1243; Yoshiyama, et al., Immunology, 61:543-547). Passive immunity from bovine antibodies offers the advantages that most animals and humans tolerate the material given orally and that the predominant antibody species present, immunoglobulin G1 (IgG1), is relatively resistant to proteolysis.

A recent study reported on the ability of bovine immunoglobulin G (IgG) concentrate (BIC) from the colostrum of cows vaccinated with *C. difficile* toxoid to protect hamsters against experimental antibiotic associated cecitis. The results indicated that the hamsters were passively immunized against the disease if they were treated before the onset of diarrhea. The authors indicated that they were unable to effectively treat the hamsters with the hyperimmune BIC once they developed diarrhea (Lyerly, et al., Infection and Immunity, Vol. 59, No. 6, pages 2215-2218 (1991)).

Thus, there is still a strong need for a method for effective treatment of antibiotic associated diarrhea, pseudomembranous colitis and *Clostridium difficile* colitis in humans without the fear of relapse in a significant amount of the patient population.

SUMMARY OF THE INVENTION

Accordingly the present invention includes a method of treating diseases associated with *C. difficile* colitis in a mammal, comprising: administering to said
5 mammal an effective amount of an antibody having specific activity against *C. difficile* and toxins thereof found in the colon. Such diseases include, for example, *Clostridium difficile* colitis, pseudomembranous colitis, and antibiotic associated diarrhea.

10 A second aspect of the present invention is a pharmaceutical composition for use in treatment of diseases associated with *C. difficile* including, for example, pseudomembranous colitis or antibiotic associated diarrhea, in a patient, comprising: an
15 effective amount of an antibody in combination with a pharmaceutically acceptable carrier adapted for oral or rectal administration, or enteric installation, the antibody having specific activity against *C. difficile* and toxins thereof.

20 A third aspect of the present invention is a pharmaceutical composition for use in treatment of pseudomembranous colitis or antibiotic associated diarrhea comprising: a combination of (a) an effective amount of an antibody having specific activity against
25 *C. difficile* and toxins thereof, and (b) an effective amount of vancomycin, bacitracin, or metronidazole, in combination with a pharmaceutically acceptable carrier.

Finally, a fourth aspect of the present invention is a method of treating pseudomembranous colitis or
30 antibiotic associated diarrhea in a patient comprising: administering to said patient an effective amount of an antibody having specific activity against *C. difficile* and toxins thereof concurrently or following the administration of an effective amount of vancomycin,
35 bacitracin or metronidazole.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graphic illustration of Anti-*clostridium difficile* Toxin A antibody levels by the ELISA method.

5 Figure 2 is a graphic illustration of Anti-*clostridium difficile* Toxin B antibody levels by the ELISA method.

10 Figure 3 is a photomicrograph of monolayer of IMR-90 fibroblasts after exposure to *C. difficile* culture filtrate (x10 minimum cytotoxic dose) for 24 hours. There is marked cytopathic effect with rounding of all cells.

15 Figure 4 is a photomicrograph of a monolayer of IMR-90 fibroblasts exposed for 24 hours to *C. difficile* culture filtrate (x10 minimum cytotoxic dose) preincubated with antifiltrate BIC (100 mg/ml). The anti-filtrate BIC effectively inhibited the cytopathic effect and the monolayer demonstrates a normal morphology.

20 Figure 5 is a graphic illustration of Anti-*clostridium difficile* BIC inhibiting binding of Toxin A to its enterocyte receptor.

25 Figure 6 is a graphic block illustration showing the effect of Bovine Immunoglobulin Concentrate (BIC) on *Clostridium difficile* culture filtrate induced fluid secretion in rat ileal loops.

 Figure 7 is a graphic block illustration showing the effect of BIC on *C. difficile* culture filtrate induced mannitol permeability in rat ileal loops.

30 Figure 8 is a graphic block illustration showing effect of BIC on *C. difficile* culture filtrate induced enteritis in rat ileal loops.

 Figure 9 is a photomicrograph of ileal tissue exposed to *C. difficile* culture filtrate.

35 Figure 10 is a photomicrograph of ileal tissue exposed to *C. difficile* culture filtrate preincubated with anti-*C. difficile* filtrate BIC.

DETAILED DESCRIPTION OF THE INVENTION

Current therapies for *C. difficile*, antibiotic associated, diarrhea and colitis use antimicrobials such as metronidazole, bacitracin or vancomycin. These agents result in further disruption of the colonic flora and are associated with a 10-20% incidence of relapsing diarrhea. The present invention provides an effective treatment which would not disturb the colonic flora. Anti-*C. difficile* bovine immunoglobulin concentrate (BIC) was prepared from the colostral milk of Holstein cows previously immunized with *C. difficile* toxoid (as described below in detail). This concentrate contained high levels of bovine IgG specific for *C. difficile* toxins A and B as evaluated by ELISA. Anti-*C. difficile* BIC neutralized the cytotoxic effects of both *C. difficile* toxin A and B whereas control, non-immune, BIC did not. Anti-*C. difficile* BIC also inhibited the enterotoxic effects of *C. difficile* toxins on rat ileum as measured by increased rat ileal loop weight/length ratio (64% inhibition, $P < 0.01$), increased mannitol permeability (89% inhibition, $P < 0.01$) and histologic grading of enteritis ($P < 0.01$ versus non-immune BIC). Thus, anti-*C. difficile* BIC neutralizes the cytotoxic effects of *C. difficile* toxins in vitro and inhibits their enterotoxic effects in vivo.

As a result of the above experiments, (described in greater detail in the examples) the inventors have discovered that administration of an immunoglobulin product containing specific antibodies to *C. difficile* results in the elimination of *C. difficile* toxins and also killing the bacteria within the colon and as such provides a realistic approach for effectively treating *C. difficile* associated diseases such as colitis, pseudomembranous colitis and antibiotic associated diarrhea and especially for patients experiencing multiple relapses.

For purposes of the present invention, the term "antibody having specific activity against *Clostridium difficile* and toxins thereof" is synonymous with "Anti-*C. difficile* bovine immunoglobulin concentrate (BIC)".

5 The antibodies may be employed alone as a liquid or solid, preferably in a solid powder form and preferably in admixture with a carrier to form a pharmaceutical composition such as a tablet, capsule or suppository. Since preferred methods of administration are oral and
10 rectal, or enteric installation, and most preferred is oral, tablets and capsules are especially preferred, or enteric installation. These, of course, are prepared according to conventional methods known in the art. The antibodies may also be combined with other
15 pharmaceutically acceptable carriers such as various liquids, proteins or oils which may also provide additional nutritional and/or pharmaceutical benefits.

 Since the effect of the antibody is dependent on reaching the colon, preferred tablets or capsules should
20 be enteric coated. Alternatively, the active antibodies can themselves be microencapsulated prior to formulation. Preparation of microcapsules of antibody as well as preparation of enteric coated tablets or capsules can be achieved by conventional methods known
25 in the art.

 Because the present antibodies first eliminate the *C. difficile* toxins, it is also advantageous to administer to patients suffering from *C. difficile* associated diseases a combination of the antibodies of
30 the present invention with antibiotics prior known for treating pseudomembranous colitis and/or antibiotic associated diarrhea. Such antibiotics are for example vancomycin, bacitracin and metronidazole. Because of the speedy and quick elimination of the *C. difficile*
35 toxins, the combination of antibody and antibiotic may be synergistic requiring much less antibiotic normally used in treating such diseases with results of decreased

symptoms development, faster symptomatic relief and lower relapse rate. Recognized doses for administering metronidazole for example is 250 mg four times a day, and oral vancomycin is 125 mg four times a day.

- 5 Administration of these antibiotics with the antibody of the present invention would result in use of substantially reduced dosage of antibiotics.

The administration of such a combination may be in a single dosage form where both active ingredients are
10 combined and mixed with a pharmaceutically acceptable carrier. Preferred compositions would be those adapted for oral or rectal administration and it would include enteric coated tablets, capsules or suppositories.

The administration of the combination concurrently
15 or following one another in separate dosage forms may still be formulated together in divided tablets or capsules. These are also known in the pharmaceutical art.

Treatment of patients suffering from *C. difficile*
20 associated diseases with the combination of two active ingredients can take place not only concurrently in a single or separate dosage form but also following administration of one ingredient with the other. Preferably administration of the antibody followed by
25 administration of the antibiotic would result in an effective treatment of the diseases.

The antibody of the present invention is contained in an immunoglobulin fraction provided to a patient. In such form, the amount of immunoglobulin provided to the
30 patient is about 1 gram per day. Typically amounts from about 1 to 20 gram per day will be used. For example, about 1 to 2 grams of immunoglobulin could be given to a patient 3 to 4 time per day. The doses of the antibody formulation to be administered will depend upon the
35 patient and the patient's medical history. Dosages of the specific antibody for adult humans envisioned by the present invention and considered to be therapeutically

effective will range from between about 0.1 to 500 mg. However, it is to be understood that doses can readily be adjusted to provide appropriate amounts of the antibody to any patient, including children.

- 5 The invention is further described by reference to the following detailed examples, wherein the methodologies are as described below. These examples are not meant to limit the scope of the invention that has been set forth in the foregoing description.
- 10 Variation within the concepts of the invention are apparent to those skilled in the art. The disclosures of the cited references are incorporated by reference herein.

EXAMPLE 1

15 Antibody production in Cows

- Toxoid was prepared from *C. difficile* VPI 10463 culture filtrate, which contains high levels of toxin A and B. The strain was grown in brain heart infusion dialysis flasks at 37°C for 72 h as previously described
- 20 (Sullivan, et al., Infect. Immun., 35:1032-1040) for the production of culture filtrate. The culture filtrate was subsequently converted to toxoid by adding 1/100 volume of formalin and incubating the mixture at 37°C for 1 h. Analysis of the toxoid by tissue culture assay
- 25 and mouse assay demonstrated that it retained <1% of its original cytotoxic and lethal activity. The challenge strain used in the animal model was *C. difficile* VPI 7698, which was isolated from a patient with
- 30 pseudomembranous colitis and which produces intermediate levels of toxins A and B. Both bacterial strains were obtained from the anaerobe collection housed in the Department of Anaerobic Microbiology at Virginia Polytechnic Institute and State University (Blacksburg, Va.).

- 35 A total of 14 gestating Holstein cows were maintained according to generally accepted dairy management practices at the Land O'Lakes Answer Farm

(Webster City, Iowa) or the research farm at Virginia Polytechnic Institute and State University. The cows were injected subcutaneously with 5 ml of toxoid (ca. 5 mg protein) emulsified in 5 ml of incomplete Freund
5 adjuvant. Cows received multiple immunizations which began at least 60 days prior to the expected calving date. Test bleed samples were taken at the time of injection.

Colostrum was collected from the first six milkings
10 of hyperimmunized cows and frozen within 2 to 3 h of collection. Colostrum was stored frozen until ready for processing. Briefly, the colostrum from all 14 cows was thawed, pooled and centrifuged to reduce the fat component. The pH was lowered to precipitate the
15 casein. The pH of the supernatant was then readjusted and the material was heat treated to reduce the bioburden. Ultrafiltration was used to reduce the lactose and mineral content. The material was heat treated again and spray dried to produce the bulk
20 immunoglobulin concentrate as a shelf-stable powder. A nonimmune IgG concentrate from the colostrum of nonvaccinated cows was prepared in a similar fashion.

EXAMPLE 2

To confirm that immunization of cows with *C. difficile* antigens is associated with a subsequent
25 increase in specific anti-*C. difficile* IgG in their colostrum milk.

ELISA Method

30 Bovine IgG levels to *C. difficile* were measured by ELISA using a modification of the method previously described (C.P. Kelly et al., Gastroenterology 1992; 102:35-40; D.Y.M. Leung et al., J. Pediatr. 1991; 118:633-637). Coating antigens used to measure IgG
35 titers included purified *C. difficile* toxin A and purified *C. difficile* toxin.

Toxigenic *Clostridium difficile* was cultured for 72 hours in brain heart infusion broth (Beckton Dickinson, Cockeysville, MD). The conditioned medium was centrifuged and the supernatant filter sterilized by passage through a 45um filter (Nalgene). *C. difficile* toxins A and B were purified from the broth culture supernatant as previously described (C. Pothoulakis et al., J. Clin. Invest. 1991; 88:119-125). Microtiter plates (Immulon II, Dynatech) were coated with *C. difficile* toxin A or toxin B (each at 10 ug protein per ml in carbonate buffer pH 9.6, 100ul per well) by incubation for 2 hours at 37°C followed by overnight incubation at 4°C. Plates were washed between each incubation step using phosphate buffered saline with 0.05% Tween 20 (PBS-T). Plates were then blocked with 2% human serum albumin (ICN, 100 ul/well) in PBS incubated for 1 hour at room temperature.

The following BIC preparations were tested: i) *C. difficile* culture filtrates immune, lot #900918 ("#18") and lot #921019 ("#19"), ii) *C. difficile* toxin A immune, lot #900927 ("#27"), and iii) control, "non-immune" BIC, lot #910311 ("#11"). All BIC samples were diluted in PBS-T (serial halving dilutions) and 100 ul per well of sample was incubated for one hour at 37°C. All assays were performed in triplicate.

Horseradish peroxidase-labeled goat anti-bovine IgG (KPL Laboratories) was used as the secondary antibody (0.2 ug/ml in PBS with 2% human serum albumin) incubated for one hour at 37°C. TMB microwell peroxidase substrate (KPL Laboratories) was used as substrate (100 ul/well) and stopped after 2 to 5 minutes with an equal volume of 1M phosphoric acid. The optical density was then read at 450 nm with 630 nm as reference using an automated photometer (Dynatech). Controls included substitution of the secondary antibody with peroxidase labeled anti-human IgG and omission of the peroxidase substrate solution. Results are expressed at the mean

optical density of test wells minus mean optical density of background wells (coated with human serum albumin alone).

Both the anti-filtrate and the anti-toxin A BIC
5 preparations had substantially higher IgG antibody
levels to purified toxin A. In this instance the
highest antibody levels were in colostrum from toxin A
immunized animals [Figure 1]. Increased IgG antibody
levels to purified toxin B were evident in the anti-
10 filtrate BIC. Anti-toxin A BIC showed a marginal
increase in toxin B antibody levels as compared to
control when assayed on a weight for weight basis
[Figure 2].

C. difficile Whole Cell Bovine Antibody Binding:

Toxigenic intact *C. difficile* were washed to remove extracellular toxins, diluted in pH 9.6 carbonate buffer and incubated overnight at 4°C in a microtiter plate to bind bacteria to plate. Bovine Immunoglobulin Concentrate (BIC powder, nonimmune and immune to *C. difficile* antigens, was incubated with the bound intact *C. difficile*. Affinity purified, peroxidase-labeled goat antibody to bovine immunoglobulin (heavy and light chain) and tetramethylbenzidine substrate was used to detect the quantity of bovine immunoglobulin bound to the intact *C. difficile*. Antibody binding was quantitated by reading the absorbance at 480 nm of the wells in the microtiter plate.

Results:

C. difficile toxin A immune BIC lot #900927 has eight time more specific antibody activity to whole cell toxigenic *C. difficile* than nonimmune BIC lot #910311.

C. difficile culture filtrate immune BIC lot #921019 has four to eight time more specific antibody activity to whole cell toxigenic *C. difficile* than nonimmune BIC lot #910311.

EXAMPLE 3

Bactericidal Activity of Bovine Antibody to *C.*

difficile:

Log phase toxigenic *C. difficile* was combined with either BIC powder immune to *C. difficile* toxins or media alone to serve as a 100% growth control. After a four hour incubation at room temperature in an anaerobic chamber, the bacteria + BIC and the bacteria + media were serially diluted in media and then plated onto tryptic soy blood agar (TSBA) plates. The TSBA plates

were incubated for 16 hours at 37°C in an anaerobic chamber and then individual bacteria colonies were counted.

Results:

5 *C. difficile* toxin A immune BIC lot #900927 reconstituted at 10% (weight/volume) and further diluted 1:2 (final) kills -90% of *C. difficile* in the reaction culture.

10 *C. difficile* culture filtrate immune BIC lot #921019 reconstituted at 10% (weight/volume) and further diluted 1:2 (final) kills 90-95% of *C. difficile* in the reaction culture.

15 See also Table 1.

TABLE 1

Bactericidal Effects of Bovine Immunoglobulin Against Toxigenic *C. difficile*

	<u>Sample</u> <u>1:10,000</u>	<u>Colonies @ 1:1000</u>	<u>Colonies @</u>
25	Bacteria + Media Control	>300	203
	BIC #921019 @ 1:2 + Bacteria	4	1
30	Bacteria + Media Control	>300	21
	BIC #900927 @ 1:2 + Bacteria	75	1

EXAMPLE 4

35 To demonstrate that anti-*C. difficile* BIC is capable of inhibiting the cytotoxic effects of *C. difficile* toxins.

Cytotoxicity Method

40 Cytotoxicity was determined by cell rounding of confluent monolayers of IMR-90 fibroblasts in tissue culture. The cytotoxic effects of *C. difficile* culture filtrate and of purified *C. difficile* toxins A and B

were examined. The minimum cytotoxic dose of each preparation was defined as the minimum dose resulting in 100% cell rounding at 24 hours (0.1-1 ng of protein/ml for culture filtrate, 10-25 ng/ml for toxin A and 0.003 ng/ml for toxin B, the ranges representing the varying potency of the different toxin preparations used in these studies). The neutralizing activity of the various BIC preparations were quantified by adding halving dilutions of BIC to either the minimum cytotoxic dose of each toxin preparation or to 10 times the minimum cytotoxic doses and assessing cell rounding after 24 hours. In each instance results are expressed as the lowest concentration of BIC required to prevent rounding of >50% of the IMR-90 cells.

Results:

Results for the cytotoxicity inhibition experiments are summarized in Tables 2 & 3. Figure 3 is a photomicrograph of an IMR-90 monolayer which had been exposed to x10 the minimum cytotoxic dose of *C. difficile* culture filtrate for 24 hours. All cells demonstrate cell rounding typical of the cytopathic effects of *C. difficile* toxins. Figure 4 illustrated a similar IMR-90 monolayer which was also exposed to the same concentration of *C. difficile* filtrate. In this instance, however, the filtrate was incubated for 1 hour at room temperature with anti-*C. difficile* BIC (#18, 100 ug/ml) prior to its addition to the monolayer. The anti-*C. difficile* filtrate BIC effectively prevented the cytotoxic effects of *C. difficile* toxins.

16

TABLE 2

(circa x10 Minimum Cytotoxic Dose)

5		Culture Filtrate (10 ng/ml)	Toxin A (250 ng/ml)	Toxin B (0.03 ng/ml)
	BIC Preparation			
10	Anti-Filtrate (#18)	6 ug/ml	1 mg/ml	8 ug/ml
	Anti-Toxin A (#27)	> 1 mg/ml	> 1 mg/ml	> 1 mg/ml
15	Control BIC (#11)	> 1 mg/ml	> 1 mg/ml	> 1 mg/ml

TABLE 3

(circa x1 Minimum Cytotoxic Dose)

20		Culture Filtrate (0.1 ng/ml)	Toxin A (10 ng/ml)	Toxin B (0.003 ng/ml)
25	BIC Preparation			
	Anti-Filtrate (#18)	0.02 ug/ml	60 ug/ml	<0.5 ug/ml
	Anti-Toxin A (#27)	12 ug/ml	500 ug/ml	8 ug/ml
30	Control BIC (#11)	25 ug/ml	> 1 mg/ml	31 ug/ml

35 Anti-*C. difficile* culture filtrate BIC (#18) effectively blocked the cytotoxic effects of *C. difficile* culture filtrate and of purified toxin A and toxin B. Anti-toxin A BIC (#27) was less effective in inhibiting cytotoxicity.

40

EXAMPLE 5

To demonstrate that anti-*C. difficile* BIC is capable of blocking the binding of *C. difficile* toxin A to its enterocyte brush border receptor.

45

Method

Purified *C. difficile* toxin A was ^3H -labelled using a modified Bolton-Hunter protocol as previously described (C. Pothoulakis et al., J. Clin. Invest. 1991; 88:119-125). Radiolabelled toxin A migrates identically to native toxin on both SDS-PAGE and HPLC and retains full biological activity as a cytotoxin (IMR-90 fibroblast rounding assay) and enterotoxin (rabbit ileal loop assay). In earlier studies using ^3H -toxin A, the presence of a single class of toxin A receptors on rabbit ileal brush border with a K_d of $5.4 \times 10^{-8}\text{M}$ and a maximum binding capacity of 5.9 pmol toxin A/mg brush border protein was demonstrated. Brush border membranes (BBM) were purified, from rabbit ileum by EDTA-chelation as previously described in the above reference. The purity of the BBM was determined by light microscopy and by measurement of alkaline phosphatase and sucrase activity.

Toxin A-BBM binding experiments were performed in triplicate in 1.8 ml Eppendorf tubes precoated with 5% skim milk in 50 mM Tris, 0.2 M NaCl (pH 7.4). Anti-*C. difficile* BIC (30 μl) at varying concentrations was incubated with 200 ng of ^3H -toxin A (approximately 35,000 dpm/pmol specific activity) in 145 μl 50 mM Tris (pH 7.4) for 2 hours at 20°C. The samples were then cooled to 4°C and 200 μg of purified BBM in 25 μl of 50 mM Tris was added. Following a one hour incubation at 4°C 1ml of 50 mM Tris buffer was added and the tubes centrifuged for 4 min at 11,000 g. The BBM pellets were washed twice with 1 ml of 50 mM Tris and then dissolved in 0.4 ml of buffer containing 10% SDS. Membrane associated radioactivity was measured by liquid scintillation counting. Results are expressed as specific toxin A binding. Specific binding being defined as total ^3H -toxin A bound minus ^3H -toxin A bound in the presence of 100 fold excess native, unlabelled, toxin A.

Results

Results are illustrated in Figure 5 (expressed as mean \pm SE). Specific toxin A binding is expressed as pmol of ^3H -toxin A bound per gram of brush border

5 membrane protein (pmol/g).

Anti-filtrate BIC (#18) inhibited the specific binding of ^3H -toxin to brush border membrane in a dose-dependent fashion. At a concentration of 15 ug/ml the anti-filtrate BIC completely blocked toxin A-receptor
10 binding. The anti-toxin A BIC also substantially reduced toxin A binding in a dose-dependent manner. At a concentration of 15 ug/ml the anti-toxin A BIC blocked toxin A-receptor binding by 84% in comparison with the same concentration of control, non-immune BIC.

15 Bovine immunoglobulin concentrate from cows immunized against *C. difficile* culture filtrate or *C. difficile* toxin A are capable of reducing the specific binding of toxin A to purified rabbit brush border membrane. Inhibition of toxin A-receptor binding
20 presumably results from binding of bovine IgG anti-toxin to toxin A thereby blocking subsequent toxin-receptor interaction. This represents a putative mechanism of action for the protective effects of anti-*C. difficile* BIC in inhibiting the enterotoxic effects of toxin A in
25 vivo.

EXAMPLE 6

To demonstrate that anti-*C. difficile* BIC is capable of inhibiting the enterotoxic effects of *C. difficile* toxins.
30

Enterotoxigenicity Method

Fasting male Wistar rats were anesthetized by intraperitoneal injection of sodium pentobarbital.
35 Laparotomy was performed, the renal pedicles tied and ^3H -mannitol (10 uCi, NEN, Boston, MA) administered intravenously. Closed ileal loops (5cm) were then

formed and injected with 400ul of 50 mM Tris buffer (pH 7.4) or with Tris buffer containing *C. difficile* culture filtrate (20 ug of protein). The inhibitory effect of anti-*C. difficile* BIC was assessed by the addition of
5 BIC (200ug) to the toxins prior to injection into the ileal lumen. The following BIC preparations were tested: i) *C. difficile* culture filtrate immune (#18 and #19), ii) *C. difficile* toxin A immune (#27), and iii) control non-immune BIC (#11).

10 The abdominal incision was closed and anaesthesia maintained with sodium pentobarbital. The animals were sacrificed after 4 hours and the ileal loops immediately harvested. Loop weight to length ratio was determined as a measure of enterotoxin effect. Mannitol excretion,
15 indicating intestinal permeability, was measured by counting radioactivity in the luminal fluid. Ileal tissue samples were also fixed in formalin, paraffin-embedded and sections stained with hematoxylin and eosin. The histologic severity of enteritis was graded
20 taking into account the following features: i) neutrophil margination and tissue infiltration, ii) hemorrhagic congestion and edema of the mucosa, iii) epithelial cell damage. A score of 0 to 3, denoting increasingly severe abnormality, as assigned to each of
25 these parameters by a blinded, histopathologist.

Results

As expected *C. difficile* culture filtrate showed enterotoxic effects as evidenced by substantial
30 increases in weight to length ratio [Figure 6] and mannitol excretion [Figure 7] in filtrate exposed ileal loops.

C. difficile culture filtrate immune BIC (Anti-Fil) substantially inhibited these enterotoxic effects (by
35 54% for weight/length ration [Figure 6] and by 100% for mannitol permeability [Figure 7], $P < 0.01$ for both). *C. difficile* toxin A immune BIC (Anti-TxA) effected a

similar inhibition of filtrate-induced enterotoxicity (64% for weight/length ration [Figure 6] and 89% for mannitol permeability [Figure 7], $P < 0.01$ for both).

Control, non-immune BIC did not inhibit had no
5 significant effect on the enterotoxicity of the culture.

Histologic examination of ileal loop tissue showed significant damage, reflected as an increase in Histology Score, in tissues exposed to *C. difficile* culture filtrate [Figure 8]. Anti-filtrate BIC and
10 anti-toxin A BIC both significantly attenuated the enteritis induced by the *C. difficile* filtrate as evidenced by a substantial lowering of Histology Scores. The control, non-immune, BIC had no significant protective effect.

15 Figure 9 is a photomicrograph illustrating a representative section of ileal mucosa after exposure to *C. difficile* culture filtrate. There is complete destruction of normal villous architecture. Vascular congestion (vessels at bottom center and right) as well
20 as neutrophil margination and tissue infiltration are evident. Figure 10 illustrates the protective effect of anti-filtrate BIC. The architecture is preserved apart from mild disruption and edema of the villous tips. There is minimal inflammatory infiltrate or congestion
25 of the submucosal vessels.

C. difficile culture filtrate immune BIC substantially inhibits filtrate-induced enterotoxicity in rat ileum. A similar degree of inhibition is seen in *C. difficile* toxin A immune BIC. These data are
30 consistent with our previous findings that *C. difficile* toxin-induced enterotoxicity in rodent intestine is mediated by toxin A. Toxin B has no demonstrable enterotoxic effects in this animal model, although toxins A and B may act synergistically to produce
35 disease symptoms in humans.

WHAT IS CLAIMED IS:

1. A method of treating diseases associated with *Clostridium difficile* in a mammal, comprising:
5 administering to said mammal an effective amount of an antibody having specific activity against *Clostridium difficile* and toxins thereof found in the colon.
2. The method of claim 1, wherein the antibody is
10 administered in an oral or rectal dosage form.
3. The method of claim 2, wherein the dosage form is a tablet, capsule or suppository.
- 15 4. The method of claim 3, wherein the tablet or capsule is enteric coated.
5. The method of claim 2, wherein the dosage form contains the antibody in microencapsulated form.
20
6. A method of treating pseudomembranous colitis in a patient comprising: administering to the patient an effective amount of an antibody having specific activity against *Clostridium difficile* and toxins
25 thereof.
7. The method of claim 6, wherein the antibody is administered orally or rectally.
- 30 8. The method of claim 6, wherein the antibody is administered in an enteric coated tablet or capsule.
9. A method of treating antibiotic associated diarrhea in a patient comprising: administering to the
35 patient an effective amount of an antibody having specific activity against *Clostridium difficile* and toxins thereof.

10. The method of claim 9, wherein the antibody is administered orally.

11. The method of claim 9, wherein the antibody is
5 administered in an enteric coated tablet or capsule.

12. A pharmaceutical composition for use in treatment of pseudomembranous colitis or antibiotic associated diarrhea in a patient, comprising:

10 an effective amount of an antibody in combination with a pharmaceutically acceptable carrier adapted for oral or rectal administration, the antibody having specific activity against *Clostridium difficile* and toxins thereof.

15

13. A pharmaceutical composition for use in treatment of pseudomembranous colitis or antibiotic associated diarrhea comprising:

- 20 (a) an effective amount of an antibody having specific activity against *Clostridium difficile* and toxins thereof, and
- (b) an effective amount of vancomycin, bacitracin or metronidazole, in combination with a pharmaceutically
25 acceptable carrier.

14. A method of treating pseudomembranous colitis or antibiotic associated diarrhea in a patient comprising: administering to said patient an effective
30 amount of an antibody having specific activity against *Clostridium difficile* toxins thereof concurrently or following the administration of an effective amount of vancomycin, bacitracin or metronidazole.

1/10




FIG. 1

2/10




FIG. 2

3/10




FIG. 3

4/10



FIG.4

5/10




FIG. 5

6/10




FIG. 6

7/10




FIG. 7

8/10




FIG. 8


9/10

FIG. 9



10/10

FIG. 10



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/10335

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K39/40 //(A61K39/40, 31:415, 38:08, 38:12)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LANCET THE, vol. 341, 1993 LONDON GB, pages 701-702, TJELLSTRÖM BO ET AL 'Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis' see the whole document ---	1-14
X	INFECTION AND IMMUNITY, vol. 59, no. 6, 1991 WASHINGTON US, pages 2215-2218, LYERLY D.M. ET AL 'Passive immunization of Hamsters against disease caused by Clostridium difficile by use of Bovine Immunoglobulin G concentrate' cited in the application see the whole document ---	1-14

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

22 November 1995

21.12.1995

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Fernandez y Branas, F

INTERNATIONAL SEARCH REPORT

Inter. nal Application No
PCT/US 95/10335

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,94 13264 (OPHIDIAN PHARMACEUTICALS) 23 June 1994 see the whole document ---	1-14
X	INFECTION AND IMMUNITY, vol. 59, no. 3, 1991 WASHINGTON US, pages 1192-1195, CORTIER G. ET AL 'Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A' see the whole document -----	1,6,9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/10335

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-11, 14 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)